Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Agatolimod (Primary) ; Aluminium hydroxide; Malaria vaccine
- Indications Malaria
- Focus Adverse reactions; Pharmacodynamics
- 18 Jan 2008 Status change from recruiting to completed, from clinicaltrials.gov record.
- 12 Jul 2006 New trial record.